DE60335813D1 - Verfahren zur krebsdiagnose mittels gpc3-nachweis - Google Patents

Verfahren zur krebsdiagnose mittels gpc3-nachweis

Info

Publication number
DE60335813D1
DE60335813D1 DE60335813T DE60335813T DE60335813D1 DE 60335813 D1 DE60335813 D1 DE 60335813D1 DE 60335813 T DE60335813 T DE 60335813T DE 60335813 T DE60335813 T DE 60335813T DE 60335813 D1 DE60335813 D1 DE 60335813D1
Authority
DE
Germany
Prior art keywords
cancer diagnosis
cancer
gpc3 detection
gpc3
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60335813T
Other languages
English (en)
Inventor
Hiroyuki Aburatani
Yutaka Midorikawa
Kiyotaka Nakano
Yukio Ito
Susumu Tokita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Perseus Proteomics Inc
Original Assignee
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Perseus Proteomics Inc filed Critical Perseus Proteomics Inc
Application granted granted Critical
Publication of DE60335813D1 publication Critical patent/DE60335813D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4722—Proteoglycans, e.g. aggreccan
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
DE60335813T 2002-09-04 2003-09-04 Verfahren zur krebsdiagnose mittels gpc3-nachweis Expired - Lifetime DE60335813D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2002/008997 WO2004023145A1 (ja) 2002-09-04 2002-09-04 Ｇｐｃ3の検出による癌の診断方法
PCT/JP2003/011320 WO2004038420A1 (ja) 2002-09-04 2003-09-04 Gpc3の検出による癌の診断方法

Publications (1)

Publication Number Publication Date
DE60335813D1 true DE60335813D1 (de) 2011-03-03

Family

ID=31972304

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60335813T Expired - Lifetime DE60335813D1 (de) 2002-09-04 2003-09-04 Verfahren zur krebsdiagnose mittels gpc3-nachweis

Country Status (11)

Country Link
US (2) US20060014223A1 (de)
EP (1) EP1548442B1 (de)
JP (1) JP4283227B2 (de)
KR (1) KR101043921B1 (de)
CN (1) CN100554964C (de)
AT (1) ATE496301T1 (de)
AU (2) AU2002330482A1 (de)
CA (1) CA2497418C (de)
DE (1) DE60335813D1 (de)
HK (1) HK1079568A1 (de)
WO (2) WO2004023145A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338020A1 (en) * 2002-09-04 2004-03-29 Chugai Seiyaku Kabushiki Kaisha Antibody against blood-solubilized n-terminal peptide in gpc3
NZ545720A (en) * 2004-07-09 2010-01-29 Chugai Pharmaceutical Co Ltd Anti-glypican 3 antibody
CN101014367B (zh) 2004-08-24 2012-07-04 中外制药株式会社 使用抗磷脂酰肌醇蛋白聚糖-3抗体的辅助疗法
US20080003623A1 (en) * 2004-10-05 2008-01-03 Atsushi Nakajima Monitoring Agent for Seriousness of Hepatitis
WO2006046751A1 (ja) 2004-10-26 2006-05-04 Chugai Seiyaku Kabushiki Kaisha 糖鎖改変抗グリピカン３抗体
EP1923463B1 (de) * 2005-08-09 2011-10-05 Oncotherapy Science, Inc. Von glypican-3 (gpc3) abgeleitetes krebsabstossungsantigen-peptid zur verwendung bei einem hla-a2-positiven patienten und das antigen enthaltendes arzneimittel
US20070087005A1 (en) 2005-10-14 2007-04-19 Lazar Gregory A Anti-glypican-3 antibody
US7723043B2 (en) * 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
JP2010528261A (ja) * 2007-05-08 2010-08-19 ピコベラ・リミテッド・ライアビリティ・カンパニー 前立腺癌および肺癌の診断および治療方法
KR101527342B1 (ko) 2007-07-17 2015-06-09 메다렉스, 엘.엘.시. 글리피칸-3에 대한 단클론 항체
EP2196541B1 (de) * 2007-09-28 2012-11-07 Chugai Seiyaku Kabushiki Kaisha Anti-glypican-3-antikörper mit verbesserter kinetik im plasma
KR101105428B1 (ko) * 2009-02-12 2012-01-17 경북대학교 산학협력단 글리피칸-3 단백질과 특이적으로 결합하는 펩타이드
CN102180969B (zh) * 2011-01-30 2013-04-10 中国人民解放军军事医学科学院微生物流行病研究所 抗肝癌活性单克隆抗体及其应用
US20140322216A1 (en) 2011-11-08 2014-10-30 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
WO2015097928A1 (ja) 2013-12-24 2015-07-02 中外製薬株式会社 可溶性ｇｐｃ３タンパク質の測定方法
EP4119947A1 (de) 2012-12-21 2023-01-18 Chugai Seiyaku Kabushiki Kaisha Gpc3-gerichtetes arzneimittel, das einem patienten verabreicht wird, der auf die gpc3-gerichtete arzneimitteltherapie reagiert
TWI693073B (zh) * 2012-12-21 2020-05-11 日商中外製藥股份有限公司 對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
JP6691060B2 (ja) * 2014-01-17 2020-04-28 グリセリックス リミティド 診断用の細胞表面前立腺癌抗原
SG11201609014TA (en) 2014-05-08 2016-12-29 Chugai Pharmaceutical Co Ltd Gpc3 -targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
CN106414499A (zh) * 2014-05-22 2017-02-15 基因泰克公司 抗gpc3抗体和免疫偶联物
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
CN104829704B (zh) * 2014-12-15 2016-08-17 河北省科学院生物研究所 一种磷脂酰肌醇蛋白聚糖gpc3蛋白片段及其应用和制备的杂交瘤细胞株
US11376326B2 (en) 2015-07-01 2022-07-05 Chugai Seiyaku Kabushiki Kaisha GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
CN105759051B (zh) * 2016-02-25 2018-12-18 广州科方生物技术股份有限公司 一种磷脂酰肌醇蛋白聚糖-3的定量分析试剂盒及其制备方法
WO2017154839A1 (ja) * 2016-03-10 2017-09-14 国立研究開発法人国立がん研究センター 肝細胞がん患者の再発リスク予測を補助する方法、装置、コンピュータプログラム製品及びキット
WO2018131586A1 (ja) * 2017-01-10 2018-07-19 国立大学法人山口大学 抗ｇｐｃ３抗体
CN106636108A (zh) * 2017-01-25 2017-05-10 复旦大学附属中山医院 一种特异性结合gpc3的核酸适配体及其应用
CN107085109A (zh) * 2017-05-15 2017-08-22 山东大学深圳研究院 高正电荷绿色荧光蛋白在制备肝癌早期诊断试剂盒中的应用
KR102154683B1 (ko) * 2019-11-08 2020-09-11 주식회사 압타머사이언스 글리피칸-3 특이적 변형 압타머 및 이의 용도
US20240094210A1 (en) 2021-01-18 2024-03-21 Fujirebio Inc. Method for treating soluble gpc3-containing specimen in soluble gpc3 immunoassay
JP2024515201A (ja) * 2021-04-23 2024-04-05 上海復宏漢霖生物技術股▲フン▼有限公司 抗ｇｐｃ３抗体及び使用方法
CN117607440A (zh) * 2023-11-28 2024-02-27 中拓生物有限公司 一种磷脂酰肌醇蛋白聚糖3蛋白测定试剂盒及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5644026A (en) 1994-05-03 1997-07-01 La Jolla Cancer Research Foundation Epitaxin, a cell motility factor
US5760000A (en) 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
EP0773218A1 (de) 1995-11-13 1997-05-14 Mitsubishi Chemical Corporation N-(Piperazinylalkoxyphenyl)-N'-phenylalkylharnstoffderivate als ACAT-Hemmer zur Atherosklerosebehandlung
US5843937A (en) 1996-05-23 1998-12-01 Panorama Research, Inc. DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents
TW586933B (en) 1996-06-20 2004-05-11 Chugai Pharmaceutical Co Ltd Compositions for treating liver-complaints using EPO
AUPO727097A0 (en) 1997-06-10 1997-07-03 Unisearch Limited Method of treatment of hepatoma and pharmaceutical compositions for use therein
ES2324029T3 (es) * 2002-05-23 2009-07-29 Sunnybrook And Women's College Health Sciences Centre Diagnostico de carcinoma hepatocelular.

Also Published As

Publication number Publication date
HK1079568A1 (en) 2006-04-07
US9513292B2 (en) 2016-12-06
CA2497418A1 (en) 2004-05-06
EP1548442A4 (de) 2007-04-18
AU2003261943A1 (en) 2004-05-13
JPWO2004038420A1 (ja) 2006-02-23
CN1678911A (zh) 2005-10-05
US20150132782A1 (en) 2015-05-14
AU2003261943B2 (en) 2009-07-23
CA2497418C (en) 2012-02-07
EP1548442B1 (de) 2011-01-19
US20060014223A1 (en) 2006-01-19
JP4283227B2 (ja) 2009-06-24
ATE496301T1 (de) 2011-02-15
WO2004038420A1 (ja) 2004-05-06
CN100554964C (zh) 2009-10-28
KR20050057205A (ko) 2005-06-16
WO2004023145A1 (ja) 2004-03-18
KR101043921B1 (ko) 2011-06-29
AU2002330482A1 (en) 2004-03-29
EP1548442A1 (de) 2005-06-29

Similar Documents

Publication Publication Date Title
DE60335813D1 (de) Verfahren zur krebsdiagnose mittels gpc3-nachweis
DE602006020877D1 (de) Vorrichtung und verfahren zum nachweis eines analyts
EP2770328A3 (de) Verfahren zur Diagnose von Bauchspeicheldrüsenkrebs
ATE489633T1 (de) Verfahren zum frühzeitigen nachweis herzerkrankungen
WO2007030949A3 (en) Methods of diagnosing ovarian cancer and kits therefor
ATE497170T1 (de) Verfahren zur diagnose von krebserkrankungen durch messung der timp-1- glycosylationsveränderungen im zusammenhang mit der tumorgenese und metastasen
ATE428929T1 (de) Reagens, ausstattung und verfahren zur probenanalyse
CA2701341A1 (en) Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex
ATE365922T1 (de) Verfahren zur erkennung von eierstockkrebs mittels menschlichem kallikrein (hk6)
EP1715333A3 (de) Verfahren zur Signalauslesung an einem gassensitiven Feldeffekttransistor
ATE370414T1 (de) Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs
DE602005017938D1 (de) System und verfahren zur repositionierung eines diagnostischen teststreifens nach inokulation
MX2012007009A (es) Método para diagnosticar un tumor maligno.
WO2005040759A3 (en) Apparatus and methods for detecting target analyte
ATE420358T1 (de) Geräteanordnung und verfahren zum nachweis eines analyten
ATE520983T1 (de) Verfahren zum nachweis eines biomoleküls, dafür verwendeter markierungsfarbstoff und markierungskit
CA2586654A1 (en) Use of asc as a marker for colorectal cancer
DE69007898T2 (de) Verfahren zur diagnose der periodontalen krankheit mittels nachweis von alaninaminotransferase.
DE69928245D1 (de) Verfahren zur probenentnahme
ATE302947T1 (de) Verfahren zum nachweis eines lipoprotein- akutphaseprotein-komplexes
DE602006018038D1 (de) Molekulares verfahren zur diagnose von prostatakrebs
ATE437368T1 (de) Verfahren zum prüfen von mit wt1-verbundenen krankheiten
DE602004026869D1 (de) Diagnose von leberzirrhose mittels eines für menschliches protoonkogenes protein spezifischen antikörpers
ATE414904T1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2- glycoprotein-i-komplexes in vivo
ATE432364T1 (de) Sonden zum nachweis von tumorzellen